Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

ChessHere Dec. 5 at 5:47 PM

$ANIX Crap... this makes me wonder why I invested in Anix (or any other bioscience firm not using AlphaFold). search for "How AlphaFold Became The Most Important Breakthrough In Modern AI " (I don't know how to get link off youtube). I suggest watching it all but start at minute 19 if you want to skip the background. It's not internet trash - these guys recently got the Nobel prize for their work - looks like everything involving proteins is now being turned on its head with unbelievable results. Maybe this explains why big pharma is holding off on partnerships with Anixa - I guarantee you the definitely know about AlphaFold and are most like using it. Dan - I am interested in Tailwinds take on this.

1 · Reply

Ventureville Dec. 5 at 4:40 PM

$BIOV.CSE DPX validation puts this stock on similar ground as $ANIX, $RCUS, and other immuno plays that ran 80-300% this year.

0 · Reply

EK12 Dec. 5 at 2:55 PM

$ANIX Someone is nibbling slowly but surely. Small increments but fairly consistent. Looks like an institutional buyer.

0 · Reply

Davidendz Dec. 4 at 9:45 PM

Sector ripping: $RCUS +110%, $ANIX +80%, $IOVA flying. $BIOV DPX data just dropped fire. Next in line.

0 · Reply

wheresdannynow Dec. 4 at 5:40 PM

$226B immunotherapy sector up 13%/yr: $MRK +$BMY dominate, $IOVA TIL approved, $ANIX up 80% YTD. $BIOV DPX just proved best-in-class neoantigen delivery in the same wave.

0 · Reply

TDMF123 Dec. 4 at 1:46 PM

$ANIX I have to believe someone is accumulating ahead of the December 11th readout.

1 · Reply

EK12 Dec. 4 at 1:11 PM

$ANIX Based on the bid/ask - yesterday's close is holding (for now). Let's hope for some buyers to step in.

0 · Reply

moosegoose Dec. 4 at 3:06 AM

$ANIX $6+ by 2026

0 · Reply

justiceforb_85 Dec. 4 at 2:04 AM

$ANIX congrats to us few in the ticker. Prior inside buys and compelling science drew me in. Hope the P1 is promising.

0 · Reply

traderk1836 Dec. 3 at 10:46 PM

$ANIX A Surprise Surge That Caught Traders Off Guard https://therelativestrengthtrader.blogspot.com/2025/12/anix-surprise-surge-that-caught-traders.html

0 · Reply

Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript

Nov 17, 2025, 8:15 AM EST - 20 days ago

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Nov 12, 2025, 11:00 AM EST - 25 days ago

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

Nov 12, 2025, 9:00 AM EST - 25 days ago

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Nov 10, 2025, 10:30 AM EST - 27 days ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Nov 5, 2025, 8:55 AM EST - 4 weeks ago

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Oct 23, 2025, 8:45 AM EDT - 6 weeks ago

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Oct 20, 2025, 8:25 AM EDT - 6 weeks ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Oct 7, 2025, 8:30 AM EDT - 2 months ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Sep 22, 2025, 8:05 AM EDT - 2 months ago

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Sep 8, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 2, 2025, 8:54 AM EDT - 3 months ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 3 months ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:37 AM EDT - 3 months ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 18, 2025, 9:00 AM EDT - 3 months ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 12, 2025, 8:05 AM EDT - 4 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 8, 2025, 9:15 AM EDT - 4 months ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 4, 2025, 8:45 AM EDT - 4 months ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Jul 30, 2025, 8:15 AM EDT - 4 months ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 24, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 15, 2025, 3:49 PM EDT - 5 months ago

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 9, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 23, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 6 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 6 months ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 6 months ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 6 months ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

May 19, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 12, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 14, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Apr 9, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Mar 25, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Mar 24, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Mar 17, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Mar 10, 2025, 8:30 AM EDT - 9 months ago

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Mar 3, 2025, 8:00 AM EST - 9 months ago

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Feb 26, 2025, 8:00 AM EST - 10 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Feb 25, 2025, 7:30 AM EST - 10 months ago

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Feb 24, 2025, 8:00 AM EST - 10 months ago

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Feb 18, 2025, 8:00 AM EST - 10 months ago

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Feb 14, 2025, 7:00 AM EST - 10 months ago

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Feb 11, 2025, 8:30 AM EST - 10 months ago

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Feb 4, 2025, 8:30 AM EST - 10 months ago

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Jan 21, 2025, 8:30 AM EST - 11 months ago

Anixa Biosciences CEO Provides Letter to Shareholders

Dec 4, 2024, 8:30 AM EST - 1 year ago

Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10

Nov 22, 2024, 8:15 AM EST - 1 year ago

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 8:20 AM EST - 1 year ago

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

ChessHere Dec. 5 at 5:47 PM

1 · Reply

Ventureville Dec. 5 at 4:40 PM

$BIOV.CSE DPX validation puts this stock on similar ground as $ANIX, $RCUS, and other immuno plays that ran 80-300% this year.

0 · Reply

EK12 Dec. 5 at 2:55 PM

$ANIX Someone is nibbling slowly but surely. Small increments but fairly consistent. Looks like an institutional buyer.

0 · Reply

Davidendz Dec. 4 at 9:45 PM

Sector ripping: $RCUS +110%, $ANIX +80%, $IOVA flying. $BIOV DPX data just dropped fire. Next in line.

0 · Reply

wheresdannynow Dec. 4 at 5:40 PM

$226B immunotherapy sector up 13%/yr: $MRK +$BMY dominate, $IOVA TIL approved, $ANIX up 80% YTD. $BIOV DPX just proved best-in-class neoantigen delivery in the same wave.

0 · Reply

TDMF123 Dec. 4 at 1:46 PM

$ANIX I have to believe someone is accumulating ahead of the December 11th readout.

1 · Reply

EK12 Dec. 4 at 1:11 PM

$ANIX Based on the bid/ask - yesterday's close is holding (for now). Let's hope for some buyers to step in.

0 · Reply

moosegoose Dec. 4 at 3:06 AM

$ANIX $6+ by 2026

0 · Reply

justiceforb_85 Dec. 4 at 2:04 AM

$ANIX congrats to us few in the ticker. Prior inside buys and compelling science drew me in. Hope the P1 is promising.

0 · Reply

traderk1836 Dec. 3 at 10:46 PM

$ANIX A Surprise Surge That Caught Traders Off Guard https://therelativestrengthtrader.blogspot.com/2025/12/anix-surprise-surge-that-caught-traders.html

0 · Reply

BagODonuts Dec. 3 at 8:56 PM

$ANIX I’m predicting a + PR after hours. Sleeping giant is waking up.

0 · Reply

EK12 Dec. 3 at 8:53 PM

$ANIX Pushing higher into the close with 4X daily volume. No news yet. Interesting...

0 · Reply

DaBullRunner Dec. 3 at 8:53 PM

$ANIX watching closely… 🚨EPOW🚨 just received a $30M contract AH That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰

0 · Reply

research_WTR Dec. 3 at 8:39 PM

Please Robert Sassoon us for a conversation with Anixa Biosciences, Inc. Chairman and CEO Dr. Amit Kumar on Monday, December 15, 2025, at 1:00 pm ET. Register below! https://us06web.zoom.us/webinar/register/2717646934309/WN_p2GYOp4gS52zdGzhl6o4DA $ANIX #AnixaBiosciences #NASDAQ #FiresideChat #SmallCap #Stocks #Investing

0 · Reply